Differential SELEX in human glioma cell lines.

The hope of success of therapeutic interventions largely relies on the possibility to distinguish between even close tumor types with high accuracy. Indeed, in the last ten years a major challenge to predict the responsiveness to a given therapeutic plan has been the identification of tumor specific...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laura Cerchia, Carla Lucia Esposito, Andreas H Jacobs, Bertrand Tavitian, Vittorio de Franciscis
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2009
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cdbd90ceb13541a98ab2c11d4cd713ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cdbd90ceb13541a98ab2c11d4cd713ba
record_format	dspace
spelling	oai:doaj.org-article:cdbd90ceb13541a98ab2c11d4cd713ba2021-11-25T06:27:52ZDifferential SELEX in human glioma cell lines.1932-620310.1371/journal.pone.0007971https://doaj.org/article/cdbd90ceb13541a98ab2c11d4cd713ba2009-11-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19956692/?tool=EBIhttps://doaj.org/toc/1932-6203The hope of success of therapeutic interventions largely relies on the possibility to distinguish between even close tumor types with high accuracy. Indeed, in the last ten years a major challenge to predict the responsiveness to a given therapeutic plan has been the identification of tumor specific signatures, with the aim to reduce the frequency of unwanted side effects on oncologic patients not responding to therapy. Here, we developed an in vitro evolution-based approach, named differential whole cell SELEX, to generate a panel of high affinity nucleic acid ligands for cell surface epitopes. The ligands, named aptamers, were obtained through the iterative evolution of a random pool of sequences using as target human U87MG glioma cells. The selection was designed so as to distinguish U87MG from the less malignant cell line T98G. We isolated molecules that generate unique binding patterns sufficient to unequivocally identify any of the tested human glioma cell lines analyzed and to distinguish high from low or non-tumorigenic cell lines. Five of such aptamers act as inhibitors of specific intracellular pathways thus indicating that the putative target might be important surface signaling molecules. Differential whole cell SELEX reveals an exciting strategy widely applicable to cancer cells that permits generation of highly specific ligands for cancer biomarkers.Laura CerchiaCarla Lucia EspositoAndreas H JacobsBertrand TavitianVittorio de FranciscisPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 4, Iss 11, p e7971 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Laura Cerchia Carla Lucia Esposito Andreas H Jacobs Bertrand Tavitian Vittorio de Franciscis Differential SELEX in human glioma cell lines.
description	The hope of success of therapeutic interventions largely relies on the possibility to distinguish between even close tumor types with high accuracy. Indeed, in the last ten years a major challenge to predict the responsiveness to a given therapeutic plan has been the identification of tumor specific signatures, with the aim to reduce the frequency of unwanted side effects on oncologic patients not responding to therapy. Here, we developed an in vitro evolution-based approach, named differential whole cell SELEX, to generate a panel of high affinity nucleic acid ligands for cell surface epitopes. The ligands, named aptamers, were obtained through the iterative evolution of a random pool of sequences using as target human U87MG glioma cells. The selection was designed so as to distinguish U87MG from the less malignant cell line T98G. We isolated molecules that generate unique binding patterns sufficient to unequivocally identify any of the tested human glioma cell lines analyzed and to distinguish high from low or non-tumorigenic cell lines. Five of such aptamers act as inhibitors of specific intracellular pathways thus indicating that the putative target might be important surface signaling molecules. Differential whole cell SELEX reveals an exciting strategy widely applicable to cancer cells that permits generation of highly specific ligands for cancer biomarkers.
format	article
author	Laura Cerchia Carla Lucia Esposito Andreas H Jacobs Bertrand Tavitian Vittorio de Franciscis
author_facet	Laura Cerchia Carla Lucia Esposito Andreas H Jacobs Bertrand Tavitian Vittorio de Franciscis
author_sort	Laura Cerchia
title	Differential SELEX in human glioma cell lines.
title_short	Differential SELEX in human glioma cell lines.
title_full	Differential SELEX in human glioma cell lines.
title_fullStr	Differential SELEX in human glioma cell lines.
title_full_unstemmed	Differential SELEX in human glioma cell lines.
title_sort	differential selex in human glioma cell lines.
publisher	Public Library of Science (PLoS)
publishDate	2009
url	https://doaj.org/article/cdbd90ceb13541a98ab2c11d4cd713ba
work_keys_str_mv	AT lauracerchia differentialselexinhumangliomacelllines AT carlaluciaesposito differentialselexinhumangliomacelllines AT andreashjacobs differentialselexinhumangliomacelllines AT bertrandtavitian differentialselexinhumangliomacelllines AT vittoriodefranciscis differentialselexinhumangliomacelllines
_version_	1718413710777647104

Differential SELEX in human glioma cell lines.

Ejemplares similares